Pfizer is licensing an AI startup's drug discovery software to speed up antibody design
Pfizer will gain early access to Chai-3, a previously undisclosed model that doubles the antibody design success rate of its predecessor
๐บ๐ธ ๋ฏธ๊ตญ ยท "PFI" ยท ์ด 6๊ฑด
ํํฐ ๋ณด๊ธฐํ์ฌ ์ง์
50.0
0 = ๋ถ์ ์ฐ์ธ
50 = ์ค๋ฆฝ
100 = ๊ธ์ ์ฐ์ธ
์ต๊ทผ 7์ผ ๊ธฐ์ค 11,950๊ฑด์ ๋ถ์ํ ๊ฒฐ๊ณผ, ๋ด์ค ์ฌ๋ฆฌ์ง์๋ 50.0(๊ท ํ)์ ๋๋ค. ๊ธ์ 1๊ฑด(0.0%)ยท์ค๋ฆฝ 11,948๊ฑด(100.0%)ยท๋ถ์ 1๊ฑด(0.0%)์ด๋ฉฐ, ์ค๋ฆฝ ๋น์ค์ด ๋๋ ทํ๊ฒ ๋์ต๋๋ค. ์ฑํฅ ์ง์๋ ์ข ํฉ 19.1(์ค๋ ๊ท ํ)์ ๋๋ค.
Pfizer will gain early access to Chai-3, a previously undisclosed model that doubles the antibody design success rate of its predecessor
Chai Discovery is working with major drugmakers to use its latest antibody AI model to find new therapies. Now itโs in talks to raise $400 million more VC funding at a $3.4 billion valuation, Forbes has learned.
Over 30 years after he introduced s'mores to Scott Smalls in 'The Sandlot,' actor Patrick Renna is sharing the magic of the classic campfire treat with his own son.
The U.S. pharma giant will pay $650 million upfront to China's Innovent Biologics to co-develop 12 early-stage oncology programs
Innovent Biologics rose as much as 10%, after entering a strategic global licensing and collaboration agreement with Pfizer to develop oncology medicines.
Still sopping from "Seaworld Venice," Holzinger opened โPfingstspielโ (Pentecost Play) near Vienna.